Media.Player

Implantation Device to House Insulin Secreting Cells as a Treatment for Diabetes

Technology Benefits

§ The device provides a long-term, effective solution for the care of diabetes § More convenient, cost-effective than current methods of glucose monitoring and management § Requires only one minimally-invasive out-patient procedure (implantation of the small device under the skin) § The cell-based device automatically responds to changes in blood glucose, and eliminates the burden on patients to continuously self-monitor and administer insulin

Detailed Technology Description

Current treatments for diabetes include regular blood glucose monitoring and insulin injection by standard needles, insulin pens and pumps, or lancing devices. These methods are time-consuming, costly, and may fail to achieve ideal glucose levels. UCI researchers have designed a long-term solution to diabetes (both Type 1 and 2) management that is highly effective and convenient. The solution is an implantable device that regulates insulin levels without continuous patient or physician intervention. The novel device is implanted under the patient’s skin and houses exogenous insulin-producing cells. The construction of the device is such that it will become properly vascularized by the patient’s own tissues. The physical features of the device allow the housed cells to have access to nutrients and oxygen which maintains the health and functionality of the cells, and also puts the cells into contact with the patient’s blood to efficiently monitor glucose levels and respond accordingly. Prototype developed and successfully demonstrated in vivo in a murine diabetes models.

Application No.

20160082236

Others

Additional Technologies by these Inventors

• Continuous Analyte Sensor Device
• Non-Immunogenic Coating for Biomedical Devices

Tech ID/UC Case

22903/2012-203-0

Related Cases

2012-203-0

UC QuickStart

QuickStart Licensing

 This technology is available through the [ucQSProgramName] program for startups.

*Abstract

Researchers at UCI have developed an implantable medical device for the continuous maintenance of blood glucose and management of diabetes (Type 1 and 2). The device houses exogenous insulin-secreting cells which can be flushed and replenished without removal of the device.

*IP Issue Date

Mar 24, 2016

*Principal Investigator

Name: Elliot Botvinick

Department:

Name: Steven George

Department:

Name: Jonathan Lakey

Department:

Name: Bhupinder Shergill

Department:

Country/Region

USA